501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Achieves
New
Plateau
with
its FAIMS Marijuana Breathalyzer Technology
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver, British
Columbia -- October
5, 2020
--
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer
of
marijuana
breathalyzer devices for law enforcement and the workplace reports
that engineers have
achieved new,
much higher levels
of
resolving power using a new PCB design
and
the
latest
mosfet
chip
technology leading to
the
highest level of molecular specificity to date with its
Cannabix
FAIMS Beta
3.2
circuit. The Company also
reports the design of a
significantly
more
compact
FAIMS
circuit board, paving the way for a
smaller
device footprint
relative to
previous versions,
enhancing
portability.
Cannabix is using
its FAIMS
technology to isolate and
detect ?9-tetrahydrocannabinol
("THC"),
a non-volatile compound, in breath. The Cannabix
FAIMS
marijuana
breathalyzer device uses ion mobility
filtering techniques
(related to mass
spectrometry
– the
gold standard analytical technique for molecular
detection).
Cannabix
Technologies is
on the
forefront in research and development to create
point-of-care breath testing technologies for the detection
of THC
- the
psychoactive component of marijuana that causes
impairment.
Rav
Mlait, CEO stated, "The Company believes
that these latest developments with the Company's
FAIMS based detection system, open up areas of
analytical chemistry that diagnostic fields have been seeking for
chemical analysis. Our team has made
significant technological strides, even under covid
restrictions over
the last number of months."
The
Company also reports that it has recently
participated in an information
session (highlighting the
Company's breath testing technologies) with a group of
transportation, safety, policy experts primarily from
the northeastern
region of the US.
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing
accurate,
durable, portable
tools to market to enable
detection of
marijuana-impaired
driving offences on roads at a time when marijuana is becoming
legal in many global jurisdictions. Cannabix is working to develop
drug-testing devices that will detect THC- the psychoactive
component of marijuana that causes intoxication- using breath
samples. In particular, Cannabix is focused on developing breath
testing devices for detection of recent use of THC, in contrast to
urine testing for THC metabolite that requires an invasive
collection and reflects usage, days or even weeks earlier. The
devices will also be useful for other practical applications such
as testing employees in the workplace where impairment by THC can
be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including:
(i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.